GlassScriptPhysician profile
Nishan Thapa
NPI 1043795016
$5,940.55
in general payments reported to CMS, 2019-2025
24 companies · $1,284 in 2025
The $1,284 reported for 2025 was more than what 92% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $956 · 2022: $1,278 · 2023: $925 · 2024: $1,498 · 2025: $1,284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,603 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,603.14 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,231.31 | 2021-2025 | |
| Janssen Biotech, INC. | $938.41 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $543.42 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $437.51 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $399.84 | 2022-2025 | |
| Lilly USA, LLC | $388.15 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $319.61 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $240.59 | 2021-2022 | |
| Amgen INC. | $223.90 | 2024-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $198.99 | 2021-2022 | |
| Leo Pharma INC. | $149.28 | 2023-2025 | Adbry |
| Pfizer INC. | $123.63 | 2022-2023 | |
| Almirall LLC | $122.64 | 2022-2024 | Seysara |
| Arcutis Biotherapeutics, INC. | $117.13 | 2023-2025 | Zoryve |
| Incyte Corporation | $110.07 | 2022-2025 | Opzelura |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $109.28 | 2023-2025 | Cabtreo, Arazlo |
| Sun Pharmaceutical Industries INC. | $82.97 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $57.28 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $44.75 | 2021-2025 | Nemluvio |
| Dermavant Sciences, INC. | $36.97 | 2024 | Vtama |
| Botanix Sb INC | $25.56 | 2025 | Sofdra |
| Biofrontera INC. | $19.06 | 2022 | |
| Genentech USA, INC. | $13.24 | 2022 | |
| Organon LLC | $6.96 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishan Thapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.